1.Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol. 2002. 9:407–15.
Article
2.Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001. 138:152–63.
Article
3.Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005. 130:3–10.
4.Böck M., de Haan J., Beck KH., Gutensohn K., Hertfelder HJ., Karger R, et al. Standardization of the PFA-100 (R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol. 1999. 106:898–904.
5.Haubelt H., Anders C., Vogt A., Hoerdt P., Seyfert UT., Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol. 2005. 130:759–67.
6.Suzuki S., Morishita S. The relationship between the onset of labor mechanisms and the hemostatic system. Immunopharmacology. 1999. 43:133–40.
Article
7.Miller JL., Rao AK. Blood platelets and von Willebrand disease. McPherson RA, editor. Clinical diagnosis and management by laboratory methods. 21st ed.Philadelphia: WB Saunders;2007. p. 764.
Article
8.Cariappa R., Wilhite TR., Parvin CA., Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol. 2003. 25:474–9.
Article
9.Sestito A., Sciahbasi A., Landolfi R., Maseri A., Lanza GA., Andreotti F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. Cardiologia. 1999. 44:661–5.
10.Veyradier A., Fressinaud E., Boyer-Neumann C., Trossaert M., Meyer D. von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system. Thromb Haemost. 2000. 84:727–8.
Article
11.Jilma-Stohlawetz P., Hergovich N., Homoncik M., Dzirlo L., Horvath M., Janisiw M, et al. Impaired platelet function among platelet donors. Thromb Haemost. 2001. 86:880–6.
Article
12.Nitu-Whalley IC., Lee CA., Hermans C. Reassessment of the correlation between the von Willebrand factor activity, the PFA-100, and the bleeding time in patients with von Willebrand disease. Thromb Haemost. 2001. 86:715–6.
Article
13.Gill JC., Endres-Brooks J., Bauer PJ., Marks WJ Jr., Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987. 69:1691–5.
Article
14.Favaloro EJ., Soltani S., McDonald J., Grezchnik E., Easton L., Favaloro JW. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol. 2005. 124:910–7.
15.Dalby MC., Davidson SJ., Burman JF., Davies SW. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets. 2000. 11:320–4.
Article
16.Brezinski DA., Tofler GH., Muller JE., Pohjola-Sintonen S., Willich SN., Schafer AI, et al. Morning increase in platelet aggregability. Association with assumption of the upright posture. Circulation. 1988. 78:35–40.
Article
17.Bridges AB., McLaren M., Scott NA., Pringle TH., McNeill GP., Belch JJ. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J. 1993. 69:121–4.
Article
18.Rudnicka AR., Rumley A., Lowe GD., Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation. 2007. 115:996–1003.
Article
19.Moeller A., Weippert-Kretschmer M., Prinz H., Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion. 2001. 41:56–60.
Article
20.Lippi G., Franchini M., Brocco G., Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost. 2001. 85:369–70.
Article
21.Harrison P., Robinson MS., Mackie IJ., Joseph J., McDonald SJ., Liesner R, et al. Performance of the platelet function analyzer PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis. 1999. 10:25–31.
22.Ortel TL., James AH., Thames EH., Moore KD., Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost. 2000. 84:93–7.
Article
23.Eugster M., Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost. 2005. 94:1213–8.
24.Han KS., Park MH., Cho HI. Blood groups. Han KS, editor. Transfusion medicine. 3rd ed.Seoul: Korea Medical Book Publisher;2006. p. 205. (한규섭, 박명희, 조한익. 혈액형. In: 한규섭 등. 수혈의학. 제3판, 서울: 고려의학 2006 205.).
25.Heilmann EJ., Kundu SK., Sio R., Garcia C., Gomez R., Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res. 1997. 87:159–64.
26.von Pape KW., Aland E., Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res. 2000. 98:295–9.
Article
27.Koscielny J., Ziemer S., Radtke H., Schmutzler M., Pruss A., Sinha P, et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost. 2004. 10:195–204.
Article